Ketamine Troches for Neuropathic Pain: Mechanism, Evidence, and Practical Use

What Is Neuropathic Pain?

Neuropathic pain arises from damage or dysfunction in the nervous system itself — the nerves, spinal cord, or brain — rather than from tissue injury. It is often described as burning, shooting, stabbing, or electric-shock-like sensations. Common conditions that produce neuropathic pain include:

• Diabetic peripheral neuropathy: Nerve damage from chronically elevated blood sugar
• Post-herpetic neuralgia: Persistent pain after a shingles outbreak
• Complex regional pain syndrome (CRPS): A disproportionate pain response following injury, often in a limb
• Chemotherapy-induced peripheral neuropathy (CIPN): Nerve damage from cancer treatment
• Trigeminal neuralgia: Severe facial pain from trigeminal nerve dysfunction
• Spinal cord injury pain: Central neuropathic pain following spinal trauma
• Radiculopathy: Nerve root compression causing radiating pain

An estimated 7 to 10 percent of the general population experiences some form of neuropathic pain. It is notoriously difficult to treat — standard painkillers like NSAIDs and even many opioids are often ineffective because the pain originates from nerve signaling errors rather than ongoing tissue damage.

Why Ketamine for Nerve Pain?

Ketamine's primary mechanism — blocking NMDA (N-methyl-D-aspartate) receptors — is directly relevant to neuropathic pain. Here is why:

Central Sensitization

In neuropathic pain, the nervous system undergoes a process called central sensitization: the spinal cord and brain become hyperexcitable, amplifying pain signals and responding to stimuli that should not be painful (allodynia) or producing exaggerated pain responses to mildly painful stimuli (hyperalgesia). NMDA receptors are key drivers of this process. When glutamate, the brain's primary excitatory neurotransmitter, repeatedly activates NMDA receptors on spinal cord neurons, it triggers a cascade that "winds up" pain processing.

Ketamine blocks this wind-up by sitting in the NMDA receptor channel and preventing glutamate from driving the sensitization process. This mechanism is shared with other chronic pain conditions that respond to ketamine, but it is particularly relevant in neuropathic pain where central sensitization is a defining feature.

Glial Cell Modulation

Emerging research suggests ketamine may also modulate glial cells — the immune-like cells of the nervous system. In neuropathic pain states, activated glial cells release pro-inflammatory cytokines that maintain and amplify pain signaling. Ketamine appears to reduce this neuroinflammatory component, providing an additional mechanism beyond NMDA blockade.

Opioid Receptor Interactions

Ketamine has weak activity at opioid receptors and may help restore opioid sensitivity in patients who have developed tolerance. For neuropathic pain patients on long-term opioid therapy with diminishing benefit, adding ketamine may improve overall pain control — a concept supported by several clinical studies.

What the Research Shows

IV Ketamine Evidence

The strongest evidence for ketamine in neuropathic pain comes from IV infusion studies:

• A 2019 consensus guideline published in Regional Anesthesia and Pain Medicine found moderate evidence supporting IV ketamine infusions for CRPS and moderate-to-weak evidence for other neuropathic pain conditions
• Multiple randomized controlled trials have demonstrated significant pain reduction (30 to 50 percent improvement) in CRPS patients receiving multi-day IV ketamine infusions
• Post-herpetic neuralgia and diabetic neuropathy have shown mixed but generally favorable results with IV ketamine in smaller studies
• Duration of benefit after IV infusions varies widely — from days to weeks — which is a limitation of intermittent infusion protocols

Sublingual/Oral Ketamine Evidence

Research specifically on sublingual ketamine troches for neuropathic pain is more limited but growing:

• Several case series and retrospective studies report meaningful pain reduction in neuropathic pain patients using at-home sublingual ketamine, typically at doses of 50 to 200 mg per session
• A 2021 study in the Journal of Pain Research found that oral ketamine (including sublingual formulations) provided clinically significant pain relief in approximately 50 percent of patients with refractory neuropathic pain when used as an adjunct to existing treatments
• The advantage of troches over IV for neuropathic pain is sustainability: patients can use troches at home on an ongoing basis, potentially maintaining the anti-sensitization effect that wears off after single IV infusions

The bioavailability of sublingual troches is approximately 25 to 35 percent — lower than IV (100 percent) but sufficient to achieve sub-anesthetic blood levels relevant to pain modulation.

How Troches Are Used for Neuropathic Pain

Typical Protocols

Prescribers who use ketamine troches for neuropathic pain generally follow one of these approaches:

Regular maintenance dosing: Troches used 2 to 3 times per week at a consistent dose, similar to protocols for depression. The goal is sustained reduction in central sensitization over time. Doses typically range from 50 mg to 200 mg per session.

As-needed rescue use: A lower dose troche (25 to 100 mg) used during pain flares. This is more common for conditions with episodic exacerbations, such as CRPS flares or trigeminal neuralgia attacks.

Combination protocols: Troches used alongside other neuropathic pain medications (gabapentinoids, SNRIs, topical agents) as part of a multimodal approach. Ketamine is rarely the sole treatment for neuropathic pain — it works best as an adjunct.

Dosing Considerations

Neuropathic pain doses are often similar to or slightly lower than those used for depression:

• Starting dose: Typically 50 mg, as outlined in general titration guidelines
• Therapeutic range: Most patients find benefit between 50 mg and 200 mg per session
• Higher doses (>200 mg) may be considered for refractory cases but require careful monitoring for side effects and should be supervised by a provider experienced in ketamine pain management

The dissociative effects of ketamine at therapeutic doses for pain are generally mild at the lower end of the dosing range. Some patients with neuropathic pain prefer lower doses that provide pain relief without significant dissociation.

Which Neuropathic Pain Conditions Respond Best?

Based on the available evidence and clinical experience, response to ketamine troches varies by condition:

Strongest evidence / most likely to respond:

• Complex regional pain syndrome (CRPS)
• Central neuropathic pain (spinal cord injury, post-stroke pain)
• Neuropathic pain with significant central sensitization component

Moderate evidence / variable response:

• Diabetic peripheral neuropathy
• Post-herpetic neuralgia
• Chemotherapy-induced neuropathy
• Fibromyalgia (which has significant neuropathic features — see the dedicated fibromyalgia article)

Limited evidence / less predictable:

• Trigeminal neuralgia
• Phantom limb pain
• Pure peripheral neuropathies without central sensitization

The presence of central sensitization features — widespread pain, allodynia, hyperalgesia, pain that spreads beyond the original nerve territory — generally predicts better response to ketamine because NMDA blockade directly targets this process.

What to Expect During Treatment

Patients using troches for neuropathic pain should understand several practical points:

• Onset of pain relief is not immediate. While some patients notice reduced pain during or shortly after a session, the meaningful clinical benefit often builds over several weeks of regular use as central sensitization gradually reverses.
• Pain scores may fluctuate. Neuropathic pain is inherently variable. Track your pain over weeks using a dose and symptom log rather than judging effectiveness based on a single session.
• The dissociative experience is a side effect, not the goal. Unlike psychiatric applications where the altered state may contribute to therapeutic processing, pain treatment with ketamine works through pharmacological NMDA blockade. Providers typically aim for the lowest effective dose.
• Combining with other treatments is standard. Continuing your existing neuropathic pain medications (unless your provider advises otherwise) while adding ketamine is the usual approach.

Important Safety Considerations

Neuropathic pain patients considering troches should review the general safety profile and contraindications, plus these specific considerations:

• Drug interactions: Many neuropathic pain patients take gabapentin, pregabalin, or other CNS-active medications. These may potentiate ketamine's sedative effects. Review all medications with your provider using the drug interactions guide.
• Driving and activities: Pain patients often need to function during the day. Plan troche sessions during times when you do not need to drive or operate machinery — evening sessions work well for many patients.
• Bladder monitoring: Long-term, frequent ketamine use can affect bladder health. Neuropathic pain patients who may use troches for extended periods should have regular monitoring.

Finding a Provider

Not all ketamine prescribers have experience with pain management. When seeking a provider for neuropathic pain, look for:

• Experience specifically with ketamine for pain (not only psychiatric applications)
• Familiarity with your specific neuropathic pain diagnosis
• Willingness to coordinate with your existing pain management team
• A structured monitoring plan for long-term use

The finding a prescriber guide and questions to ask resource can help you identify qualified providers.

References

• Cohen SP, et al. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain. Regional Anesthesia and Pain Medicine, 2018 — Evidence-based guidelines for ketamine in chronic pain
• NIH National Institute of Neurological Disorders and Stroke: Peripheral Neuropathy — Overview of neuropathic pain conditions
• Schwartzman RJ, et al. Outpatient Intravenous Ketamine for the Treatment of Complex Regional Pain Syndrome. Pain Medicine, 2009 — Study demonstrating ketamine efficacy in CRPS
• Mayo Clinic: Neuropathic Pain — Patient-facing overview of nerve pain conditions
• Goldberg ME, et al. Multi-day Low Dose Ketamine Infusion for the Treatment of Complex Regional Pain Syndrome. Pain Physician, 2005 — Early evidence for sustained ketamine protocols in CRPS